Prediabetes in patients with stroke or transient ischemic attack: Prevalence, risk and clinical management

Cerebrovascular Diseases

Volumn 37, Issue 6, 2014, Pages 393-400

  Fonville, Susanne ^a   Zandbergen, Adrienne A M ^b   Koudstaal, Peter J ^a   Den Hertog, Heleen M ^a,c  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b IKAZIA HOSPITAL   (Netherlands)

^c MEDISCH SPECTRUM TWENTE   (Netherlands)

Author keywords

Glucose metabolism; Prediabetes; Stroke; Transient ischemic attack

Indexed keywords

ANTIDIABETIC AGENT; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; ACARBOSE; BIGUANIDE; METFORMIN; PIOGLITAZONE; ROSIGLITAZONE; SITAGLIPTIN; VALSARTAN;

BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; DIET RESTRICTION; DISEASE COURSE; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; GLUCOSE TRANSPORT; HUMAN; HYPERGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIFESTYLE MODIFICATION; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PREVALENCE; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SECONDARY PREVENTION; STROKE PATIENT; TRANSIENT ISCHEMIC ATTACK; COMPLICATION; ISCHEMIC ATTACK, TRANSIENT; PREDIABETIC STATE; RISK; STROKE; DISEASE ASSOCIATION; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; META ANALYSIS (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; RISK MANAGEMENT;

HUMANS; ISCHEMIC ATTACK, TRANSIENT; PREDIABETIC STATE; PREVALENCE; RISK; SECONDARY PREVENTION; STROKE;

EID: 84928333676     PISSN: 10159770     EISSN: 14219786     Source Type: Journal    
DOI: 10.1159/000360810     Document Type: Review

References (64)

1. Buysschaert M, Bergman M: Definition of prediabetes. Med Clin North Am 2011; 95: 289-297, vii.
2. American Diabetes Association: Diagnosis and classification of diabetes mellitus. Diabetes Care 2013; 36(suppl 1):S67-S74.
3. Colagiuri S: Epidemiology of prediabetes. Med Clin North Am 2011; 95: 299-307, vii.
4. Ford ES, Zhao G, Li C: Pre-diabetes and the risk for cardiovascular disease: a systematic review of the evidence. J Am Coll Cardiol 2010; 55: 1310-1317.
5. Lee M, Saver JL, Hong KS, Song S, Chang KH, Ovbiagele B: Effect of pre-diabetes on future risk of stroke: meta-analysis. BMJ 2012; 344:e3564.
6. Vermeer SE, Sandee W, Algra A, Koudstaal PJ, Kappelle LJ, Dippel DW: Impaired glucose tolerance increases stroke risk in nondiabetic patients with transient ischemic attack or minor ischemic stroke. Stroke 2006; 37: 1413-1417.
7. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM; Diabetes Prevention Program Research Group: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403.
8. Gillies CL, Abrams KR, Lambert PC, Cooper NJ, Sutton AJ, Hsu RT, Khunti K: Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis. BMJ 2007; 334: 299.
9. Hopper I, Billah B, Skiba M, Krum H: Prevention of diabetes and reduction in major cardiovascular events in studies of subjects with prediabetes: meta-analysis of randomised controlled clinical trials. Eur J Cardiovasc Prev Rehabil 2011; 18: 813-823.
10. Califf RM, Boolell M, Haffner SM, Bethel MA, McMurray J, Duggal A, Holman RR: Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial. Am Heart J 2008; 156: 623-632.
11. WHO: Definition, diagnosis and classification of diabetes mellitus and its complications: report of a WHO consultation. Geneva, World Health Organization, 1999.
12. American Diabetes Association: Standards of medical care in diabetes - 2012. Diabetes Care 2012; 35(suppl 1):S11-S63.
13. Kernan WN, Viscoli CM, Inzucchi SE, Brass LM, Bravata DM, Shulman GI, McVeety JC: Prevalence of abnormal glucose tolerance following a transient ischemic attack or ischemic stroke. Arch Intern Med 2005; 165: 227-233.
14. Matz K, Keresztes K, Tatschl C, Nowotny M, Dachenhausen A, Brainin M, Tuomilehto J: Disorders of glucose metabolism in acute stroke patients: an underrecognized problem. Diabetes Care 2006; 29: 792-797.
15. Urabe T, Watada H, Okuma Y, Tanaka R, Ueno Y, Miyamoto N, Tanaka Y, Hattori N, Kawamori R: Prevalence of abnormal glucose metabolism and insulin resistance among subtypes of ischemic stroke in Japanese patients. Stroke 2009; 40: 1289-1295.
16. Jia Q, Zheng H, Zhao X, Wang C, Liu G, Wang Y, Liu L, Li H, Zhong L: Abnormal glucose regulation in patients with acute stroke across China: prevalence and baseline patient characteristics. Stroke 2012; 43: 650-657.
17. Lindsberg PJ, Tuomi T, Kaste M: Oral glucose tolerance test should be performed after stroke and transient ischemic attack. Int J Stroke 2011; 6: 317-320.
18. Fonville S, Zandbergen AA, Vermeer SE, Dippel DW, Koudstaal PJ, den Hertog HM: Prevalence of prediabetes and newly diagnosed diabetes in patients with a transient ischemic attack or stroke. Cerebrovasc Dis 2013; 36: 283-289.
19. Ivey FM, Ryan AS, Hafer-Macko CE, Garrity BM, Sorkin JD, Goldberg AP, Macko RF: High prevalence of abnormal glucose metabolism and poor sensitivity of fasting plasma glucose in the chronic phase of stroke. Cerebrovasc Dis 2006; 22: 368-371.
20. Jia Q, Zheng H, Liu L, Zhao X, Wang C, Jing J, Liang D, Wang Y, Zhou Y, Dong K, Yang Z, Wang Y: Persistence and predictors of abnormal glucose metabolisms in patients after acute stroke. Neurol Res 2010; 32: 359-365.
21. Lam KS, Ma JT, Woo E, Lam C, Yu YL: High prevalence of undiagnosed diabetes among Chinese patients with ischaemic stroke. Diabetes Res Clin Pract 1991; 14: 133-137.
22. Gray CS, Scott JF, French JM, Alberti KG, O'Connell JE: Prevalence and prediction of unrecognised diabetes mellitus and impaired glucose tolerance following acute stroke. Age Ageing 2004; 33: 71-77.
23. Vancheri F, Curcio M, Burgio A, Salvaggio S, Gruttadauria G, Lunetta MC, Dovico R, Alletto M: Impaired glucose metabolism in patients with acute stroke and no previous diagnosis of diabetes mellitus. Q J Med 2005; 98: 871-878.
24. Dave JA, Engel ME, Freercks R, Peter J, May W, Badri M, Van Niekerk L, Levitt NS: Abnormal glucose metabolism in non-diabetic patients presenting with an acute stroke: prospective study and systematic review. Q J Med 2010; 103: 495-503.
25. Huisa BN, Roy G, Kawano J, Schrader R: Glycosylated hemoglobin for diagnosis of prediabetes in acute ischemic stroke patients. J Stroke Cerebrovasc Dis 2013; 22:e564-e567.
26. Abdul-Ghani MA, Tripathy D, DeFronzo RA: Contributions of beta-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose. Diabetes Care 2006; 29: 1130-1139.
27. Capes SE, Hunt D, Malmberg K, Pathak P, Gerstein HC: Stress hyperglycemia and prognosis of stroke in nondiabetic and diabetic patients: a systematic overview. Stroke 2001; 32: 2426-2432.
28. Piironen K, Putaala J, Rosso C, Samson Y: Glucose and acute stroke: evidence for an interlude. Stroke 2012; 43: 898-902.
29. Dungan KM, Braithwaite SS, Preiser JC: Stress hyperglycaemia. Lancet 2009; 373: 1798-1807.
30. Kruyt ND, Biessels GJ, Devries JH, Roos YB: Hyperglycemia in acute ischemic stroke: pathophysiology and clinical management. Nat Rev Neurol 2010; 6: 145-155.
31. Harada S, Fujita-Hamabe W, Tokuyama S: Ischemic stroke and glucose intolerance: a review of the evidence and exploration of novel therapeutic targets. J Pharmacol Sci 2012; 118: 1-13.
32. Nathan DM, Davidson MB, DeFronzo RA, Heine RJ, Henry RR, Pratley R, Zinman B; American Diabetes Association: Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care 2007; 30: 753-759.
33. Qiao Q, Pyorala K, Pyorala M, Nissinen A, Lindstrom J, Tilvis R, Tuomilehto J: Twohour glucose is a better risk predictor for incident coronary heart disease and cardiovascular mortality than fasting glucose. Eur Heart J 2002; 23: 1267-1275.
34. DECODE Study Group: Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 2001; 161: 397-405.
35. Coutinho M, Gerstein HC, Wang Y, Yusuf S: The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 1999; 22: 233-240.
36. Qureshi AI, Giles WH, Croft JB: Impaired glucose tolerance and the likelihood of nonfatal stroke and myocardial infarction: the third national health and nutrition examination survey. Stroke 1998; 29: 1329-1332.
37. Donahue RP, Dorn JM, Stranges S, Swanson M, Hovey K, Trevisan M: Impaired fasting glucose and recurrent cardiovascular disease among survivors of a first acute myocardial infarction: evidence of a sex difference? The western New York experience. Nutr Metab Cardiovasc Dis 2011; 21: 504-511.
38. Bartnik M, Malmberg K, Norhammar A, Tenerz A, Ohrvik J, Ryden L: Newly detected abnormal glucose tolerance: an important predictor of long-term outcome after myocardial infarction. Eur Heart J 2004; 25: 1990-1997.
39. Henareh L, Agewall S: 2-h postchallenge plasma glucose predicts cardiovascular events in patients with myocardial infarction without known diabetes mellitus. Cardiovasc Diabetol 2012; 11: 93.
40. Luitse MJ, Biessels GJ, Rutten GE, Kappelle LJ: Diabetes, hyperglycaemia, and acute ischaemic stroke. Lancet Neurol 2012; 11: 261-271.
41. Van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J: Interobserver agreement for the assessment of handicap in stroke patients. Stroke 1988; 19: 604-607.
42. Diener HC, Lees KR, Lyden P, Grotta J, Davalos A, Davis SM, Shuaib A, Ashwood T, Wasiewski W, Alderfer V, Hardemark HG, Rodichok L: NXY-059 for the treatment of acute stroke: pooled analysis of the SAINT I and II trials. Stroke 2008; 39: 1751-1758.
43. Poppe AY, Majumdar SR, Jeerakathil T, Ghali W, Buchan AM, Hill MD: Admission hyperglycemia predicts a worse outcome in stroke patients treated with intravenous thrombolysis. Diabetes Care 2009; 32: 617-622.
44. De Silva DA, Ebinger M, Christensen S, Parsons MW, Levi C, Butcher K, Barber PA, Bladin C, Donnan GA, Davis SM: Baseline diabetic status and admission blood glucose were poor prognostic factors in the EPITHET trial. Cerebrovasc Dis 2010; 29: 14-21.
45. Putaala J, Sairanen T, Meretoja A, Lindsberg PJ, Tiainen M, Liebkind R, Strbian D, Atula S, Artto V, Rantanen K, Silvonen P, Piironen K, Curtze S, Happola O, Mustanoja S, Pitkaniemi J, Salonen O, Silvennoinen H, Soinne L, Kuisma M, Tatlisumak T, Kaste M: Postthrombolytic hyperglycemia and 3-month outcome in acute ischemic stroke. Cerebrovasc Dis 2011; 31: 83-92.
46. Tanaka R, Ueno Y, Miyamoto N, Yamashiro K, Tanaka Y, Shimura H, Hattori N, Urabe T: Impact of diabetes and prediabetes on the short-term prognosis in patients with acute ischemic stroke. J Neurol Sci 2013; 332: 45-50.
47. Pan XR, Li GW, Hu YH, Wang JX, Yang WY, An ZX, Hu ZX, Lin J, Xiao JZ, Cao HB, Liu PA, Jiang XG, Jiang YY, Wang JP, Zheng H, Zhang H, Bennett PH, Howard BV: Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 1997; 20: 537-544.
48. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen- Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M: Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344: 1343-1350.
49. Eriksson KF, Lindgarde F: Prevention of type 2 (non-insulin-dependent) diabetes mellitus by diet and physical exercise. The 6-year Malmo Feasibility Study. Diabetologia 1991; 34: 891-898.
50. Li G, Zhang P, Wang J, Gregg EW, Yang W, Gong Q, Li H, Jiang Y, An Y, Shuai Y, Zhang B, Zhang J, Thompson TJ, Gerzoff RB, Roglic G, Hu Y, Bennett PH: The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study. Lancet 2008; 371: 1783-1789.
51. Uusitupa M, Peltonen M, Lindstrom J, Aunola S, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Valle TT, Eriksson JG, Tuomilehto J: Ten-year mortality and cardiovascular morbidity in the Finnish diabetes prevention study - secondary analysis of the randomized trial. PLoS One 2009; 4:e5656.
52. Ratner R, Goldberg R, Haffner S, Marcovina S, Orchard T, Fowler S, Temprosa M: Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the diabetes prevention program. Diabetes Care 2005; 28: 888-894.
53. Zinman B, Harris SB, Neuman J, Gerstein HC, Retnakaran RR, Raboud J, Qi Y, Hanley AJ: Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a doubleblind randomised controlled study. Lancet 2010; 376: 103-111.
54. Den Hertog HM, Vermeer SE, Zandbergen AA, Achterberg S, Dippel DW, Algra A, Kappelle LJ, Koudstaal PJ: Safety and feasibility of metformin in patients with impaired glucose tolerance and a recent TIA or minor ischemic stroke (LIMIT) trial - a multicenter, randomized, open-label phase II trial. Int J Stroke, Epub ahead of print.
55. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M: Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: The stop-NIDDM trial. JAMA 2003; 290: 486-494.
56. Chiasson JL: Acarbose for the prevention of diabetes, hypertension, and cardiovascular disease in subjects with impaired glucose tolerance: the study to prevent non-insulin-dependent diabetes mellitus (stop-NIDDM) trial. Endocr Pract 2006; 12(suppl 1):25-30.
57. Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N, Hanefeld M, Hoogwerf B, Laakso M, Mohan V, Shaw J, Zinman B, Holman RR: Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006; 368: 1096-1105.
58. Kernan WN, Inzucchi SE, Viscoli CM, Brass LM, Bravata DM, Shulman GI, McVeety JC, Horwitz RI: Pioglitazone improves insulin sensitivity among nondiabetic patients with a recent transient ischemic attack or ischemic stroke. Stroke 2003; 34: 1431-1436.
59. McMurray JJ, Holman RR, Haffner SM, et al: Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med 2010; 362: 1477-1490.
60. Saxena R, Wijnhoud AD, Koudstaal PJ, van den Meiracker AH: Induced elevation of blood pressure in the acute phase of ischemic stroke in humans. Stroke 2000; 31: 546-548.
61. Furie KL, Kasner SE, Adams RJ, Albers GW, Bush RL, Fagan SC, Halperin JL, Johnston SC, Katzan I, Kernan WN, Mitchell PH, Ovbiagele B, Palesch YY, Sacco RL, Schwamm LH, Wassertheil- Smoller S, Turan TN, Wentworth D: Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011; 42: 227-276.
62. American Diabetes Association: Standards of medical care in diabetes - 2013. Diabetes Care 2013; 36(suppl 1):S11-S66.
63. Skyler JS, Bergenstal R, Bonow RO, Buse J, Deedwania P, Gale EA, Howard BV, Kirkman MS, Kosiborod M, Reaven P, Sherwin RS: Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Diabetes Care 2009; 32: 187-192.
64. Chiasson JL: Prevention of type 2 diabetes: Fact or fiction? Expert Opin Pharmacother 2007; 8: 3147-3158